The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation
- PMID: 36697133
- DOI: 10.1016/j.jacc.2022.11.024
The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation
Keywords: ACEI; ARB; angioedema; real-world; sacubitril-valsartan.
Conflict of interest statement
Funding Support and Author Disclosures The author has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.J Am Coll Cardiol. 2023 Jan 31;81(4):321-331. doi: 10.1016/j.jacc.2022.10.033. J Am Coll Cardiol. 2023. PMID: 36697132
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
